-Reuters
Jefferies Downgrades NGM Biopharmaceuticals to Hold
Jefferies analyst Dennis Ding downgrades NGM Biopharmaceuticals (NASDAQ:NGM) from Buy to Hold.
Related Posts
Cenovus Energy: Q4 Earnings Insights
Cenovus Energy (NYSE:CVE) reported its Q4 earnings results on Tuesday, February 8, 2022 at 06:00 AM.
Here's what investors need to know about the announcement.
‘Oracle Axes U.S. Staff, Part of Plan to Lay Off Thousands’ -The Information Report
https://www.theinformation.com/articles/oracle-axes-u-s-staff-part-of-plan-to-lay-off-thousands
UBS Downgrades Newmont to Neutral, Lowers Price Target to $53
UBS analyst Cleve Rueckert downgrades Newmont (NYSE:NEM) from Buy to Neutral and lowers the price target from $59 to $53.